Sanuwave Health, Inc. · NASDAQ:SNWV
Sanuwave Health — Q4 2024 Earnings Presentation
8 slides from Sanuwave Health's earnings presentation, Mar 21, 2025
Slide 1: Q4 FY2024
(6) SANUWAVE Wound Care Technologies Q4 FY2024 March 21, 2025
Slide 2: Live Presentation and Participant Dial-in Information
Live Presentation Friday, March 21, 2025, 8:30 AM (ET) Participant Dial-in Information Toll Free: 1-800-245-3047 Toll/International: 1-203-518-9765 Conference ID: SANUWAVE OR click the link for instant telephone access to the event. https://viavid.webcasts.com/starthere.jsp?ei=1703280&tp_key=c099e4f
Slide 3: Forward Looking Statements and Non-GAAP Financial Measures
3 Forward Looking Statements and Non-GAAP Financial Measures Forward-Looking Statements This presentation may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectati
Slide 4: Financials Q4 2024
4 Financials Q4 2024 Consistent topline growth while managing operating costs. (in millions) Q4 2024 Q4 2023 YoY Revenue $10.3 $7.0 + 47% Gross Profit $8.0 $4.8 + 67% Gross Margin 77.9% 69.1% +873bp Operating Expense $5.5 $3.8 +45% Revenue Gross Profit Operating Income Operating Income $2.5 $1.0 +15
Slide 5: Improved operational results
5 Improved operational results See Non-GAAP Financial Measures disclosure included on slide 3
Slide 6: Growing UltraMist Systems & Consumables Sales
6 Growing UltraMist Systems & Consumables Sales Continuous UltraMIST revenue growth and strong year on year growth throughout 2024. $7.0 + 65% yoy • 1,047 systems in the field at $6.0 +11% seq end of Q4 2024 +54% yoy • In Q4 2024: 135 systems sold $5.0 +10% seq (vs 79 in Q4 2023 and 124 in $4.0 Q3 2
Slide 7: Q4 and FY 2025 Revenue Guidance
7 Q4 and FY 2025 Revenue Guidance Q1 2025 FY 2025 REVENUE GROWTH REVENUE GROWTH $48-50 million +45-55% (+47-53%) vs vs Q1 2024 REVENUE FY 2024 REVENUE of $5.79 million of $32.6 million
Slide 8: Summary
8 Summary Wound care is undergoing a payor led shift to evidence based medicine and reimbursement. This has aligned incentives for patients, payors, and providers. SANUWAVE is in a prime position to benefit: ▪ Approved products protected by strong IP ▪ Strong existing reimbursement with room to impr